At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 147 enrolled
Drug / intervention
Nicotinamide Riboside (NR) +1 moredrug
Likely dose
Nicotinamide Riboside (NR) 1,000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
In Brief
A Phase 1 clinical trial evaluating Walking Exercise and Nicotinamide Riboside (NR) for Hypertension. Completed, enrolled 147 participants across 1 site.
Detailed Summary
More than 80% of older adults have hypertension, with higher prevalence of high systolic blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death. Novel compound, nicotinamide riboside may enhance the effects of exercise therapy in hypertensive older adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartJul 2020
Primary CompletionMay 2023
TodayJul 2026
First PostedOct 2, 2019
Enrollment StartJul 28, 2020
Primary CompletionMay 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.8 years ago
Interventions
Walking Exercisebehavioral
Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
Nicotinamide Riboside (NR)drug
Participants randomized to this intervention will receive 1,000 mg/day of NR.